InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
InspireMD announced amendments to its Series J and Series K warrants to align their exercise triggers with the anticipated FDA approval of CGuard Prime 80 cm in Q4 2026. These amendments could provide the company with up to $11 million in gross proceeds to support the commercial launch of its carotid stent system for transcarotid artery revasculari…